EUR/USD 1.17747
0.156%
Gold 3334.89
0.269%
Oil 65.635
-1.022%
USD/JPY 144.562
-0.237%
GBP/USD 1.36511
-0.031%
GBP/JPY 197.337
-0.256%
Browse More
  • English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
The statement showed that the British government made its first ministerial visit to Syria in 14 years and re-established diplomatic relations with Syria.On July 5, the head of the Kyiv Military and Political Administration Bureau of Ukraine, Tekachenko, said that the large-scale air strike launched by Russia on Kyiv in the early morning of the 4th has so far caused 2 deaths and 31 injuries, and the number of casualties continues to rise.On July 5, European Central Bank board member Makhlouf said that if the euro wants to quickly replace the dollar as the pillar of the global financial system, countries still have a long way to go, because there are still many gaps in financial and economic integration among European countries. Makhlouf said that the dominance of the dollar will weaken in the long run, but Europe currently lacks a single fiscal asset that is as stable as U.S. Treasuries and can compete with it. "Frankly speaking, Europes economic system is not yet fully formed," Makhlouf said, adding that changes in currency exchange rates in recent months are more due to investors concerns about the rule of law in the United States. Makhlouf said: "It would be a bit of an exaggeration to say that this will suddenly push the euro to replace the dollar, because the euro does not currently have such capabilities."ECB board member Makhlouf: Euro is not ready to challenge dollars status as global reserve currency.Russian Embassy: The Russian trade mission to Sweden has come under attack again, with a drone dropping paint on its premises.

AstraZeneca's Breast Cancer Medication Could Be Used More Widely After New Results

Charlie Brooks

Jun 06, 2022 10:56

3.png


According to data published on Sunday, AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's Enhertu increased survival by more than six months in patients with advanced breast cancer compared to usual chemotherapy.


The data, which was presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago, might open a big, new multibillion-dollar patient group for the medicine that received U.S. approval late in 2019 for the 15 percent of breast cancer patients with HER2-positive illness.


Over 550 patients with so-called HER2-low breast cancer - the majority with hormone-sensitive tumors - whose disease had progressed and who had completed at least one round of chemotherapy are participating in the ongoing phase III research.


The interim analysis revealed that Enhertu increased survival by an extra 6,4 months in hormone-sensitive tumor patients. The group had a median survival rate of 23.9 months, compared to 17.5 months for chemotherapy patients.


In the small sample of patients with hormone-resistant tumors, Enhertu improved survival by 6.3 months.


David Fredrickson, executive vice president of AstraZeneca's oncology unit, expressed surprise to Reuters that the improvement in overall survival was obvious even at the interim analysis point.


This provides a great deal of assurance that the benefit we are observing here is genuine.


The prognosis for individuals with advanced HER2-positive breast cancer has been vastly improved by a variety of targeted therapy. More than half of women whose breast cancer has progressed to other organs and express little or no HER2 have restricted therapeutic options; this is known as HER2-low status.


It was statistically significant that hormone-sensitive patients who got Enhertu had a progression-free survival (PFS) of 10.1 months on average, compared to 5.4 months for chemotherapy.


Enhertu more than doubled the PFS for hormone-insensitive individuals, from 2.9 months with chemotherapy to 6.6 months with Enhertu.


AstraZeneca is in talks with regulators worldwide regarding authorisation for the HER2-low population. Analysts at Jefferies predicted last month that annual global peak sales of Enhertu for these patients would reach $2.5 billion, and around $6.6 billion for all indications.


There are safety issues with the medicine, which is provided by intravenous infusion. It has been associated with interstitial lung disease, a form of lung scarring (ILD). In the trial, 45 Enhertu patients developed varied degrees of ILD, compared to one patient in the chemotherapy group.


Enhertu is part of a therapeutic class known as antibody drug conjugates (ADC), which are designed antibodies that bind to cancer cells and release cell-killing chemicals.


A study showed that it lowered the risk of disease progression or death by 72% when compared to Roche's Kadcyla, the standard treatment. It was approved as a second-line treatment option last month.


Enhertu is being studied for usage in breast cancer's earliest stages, as well as lung and colorectal malignancies. It has been approved for HER2-positive stomach cancer.


Reuters quoted Tara Hansen, a consultant at Informa Pharma Custom Intelligence, as saying, "As far as breast cancer is concerned, I'm rather certain that Enhertu will finish revolutionizing the therapy paradigm over the next five years."


In 2021, Enhertu generated $214 million in revenue. Three years ago, AstraZeneca acquired partial rights to the Daiichi Sankyo chemical in a deal valued up to $6.9 billion.


Suggestion